Teva Pharmaceutical Industries (NYSE:TEVA) Releases Earnings Results, Beats Estimates By $0.14 EPS

Teva Pharmaceutical Industries (NYSE:TEVA) announced its earnings results on Tuesday. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14, FiscalAI reports. Teva Pharmaceutical Industries had a return on equity of 33.22% and a net margin of 2.94%. The firm had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same quarter in the previous year, the business earned $0.78 EPS. The company’s quarterly revenue was down 1.9% on a year-over-year basis.

Here are the key takeaways from Teva Pharmaceutical Industries’ conference call:

• Teva raised its 2026 guidance, including revenue to $16.7–$17.0 billion and free cash flow to $2.1–$2.4 billion, supported by strong growth in AUSTEDO, AJOVY, and UZEDY. Non-GAAP EPS rose 10% year over year to $0.86, while gross margin expanded to 58.7%.
• The innovative portfolio continued to accelerate: AUSTEDO reached its $2.5 billion sales target a year early, UZEDY revenue increased 96% to $85 million, and AJOVY revenue rose 61% to $269 million. Teva raised full-year product outlooks for all three brands and expects continued long-term growth.
• FDA approval of WELTRUZA, a once-monthly long-acting olanzapine injection, expands Teva’s neuroscience franchise; management expects limited revenue in the first half of 2027 while payer coverage is established, with more meaningful contribution in the second half. Teva estimates the combined UZEDY/WELTRUZA franchise can reach $1.5–$2.0 billion in peak sales.
• Biosimilars are becoming a major growth engine, with Teva achieving its $800 million 2027 sales target a year early and expanding to 15 marketed products plus a broader pipeline. The company also reached investment-grade ratings from all three major agencies and remains on track for net debt leverage of approximately 2x EBITDA by the end of 2027.
• Generic revenue declined 16%, primarily because of lower generic REVLIMID contribution, and AUSTEDO is expected to decline year over year in Q4 due to purchasing patterns and pricing pressure ahead of IRA implementation. Separately, Teva discontinued the emrusolmin Phase II study after a futility analysis, although management reported no safety concerns.

Teva Pharmaceutical Industries Trading Up 0.2%

Shares of TEVA stock traded up $0.07 on Thursday, reaching $41.92. 9,985,667 shares of the company’s stock were exchanged, compared to its average volume of 6,831,346. Teva Pharmaceutical Industries has a 52 week low of $23.61 and a 52 week high of $43.34. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56. The stock has a market capitalization of $48.85 billion, a PE ratio of 97.28, a P/E/G ratio of 3.89 and a beta of 0.97. The company’s fifty day simple moving average is $39.32 and its 200 day simple moving average is $34.68.

Analyst Ratings Changes

Several research analysts have commented on the stock. TD Cowen lifted their price objective on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a research note on Wednesday. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an “overweight” rating in a research note on Thursday, October 15th. UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, September 4th. Zacks Research lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Finally, HC Wainwright initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Monday. They set a “buy” rating and a $52.00 price target for the company. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $46.69.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva’s Q3 adjusted earnings of $0.86 per share exceeded the $0.72 consensus, while revenue of $4.40 billion also topped estimates. Strong branded-drug sales helped prompt higher 2026 revenue and product-sales guidance, supporting optimism about growth beyond generics. Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
• Positive Sentiment: TD Cowen raised its price target to $57 from $55 and maintained a Buy rating. HC Wainwright also rates Teva Buy, with a $52 target and a forecast of $3.03 EPS for 2027; the positive research supports the longer-term earnings-growth case. TD Cowen Teva rating HC Wainwright coverage
• Positive Sentiment: A new agreement with Samsung Bioepis gives Teva U.S. rights to commercialize two FDA-approved biosimilars, expanding its portfolio and potential revenue sources. Teva and Samsung biosimilar agreement
• Neutral Sentiment: Quarterly revenue was down 1.9% from a year earlier, indicating ongoing pressure despite beating estimates. The raised outlook and branded-drug performance partly offset that concern. Teva stock: Q3 revenue slips as 2026 outlook rises
• Negative Sentiment: Teva stopped its Phase 2 emrusolmin study after an interim analysis found insufficient efficacy. The decision removes a development opportunity, though the company reported no safety concerns; management separately raised UZEDY’s sales outlook. Why Teva Is Dropping a Drug Trial While Raising Its Outlook

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 367,600 shares of the company’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $39.06, for a total value of $14,358,456.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Brian Savage sold 7,342 shares of the stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the sale, the insider owned 8,500 shares in the company, valued at approximately $330,225. The trade was a 46.35% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.54% of the stock is owned by insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.